A recent study indicates that patients who come off blockbuster slimming jabs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs.
Published data in a major health publication shows that while overweight people frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Individuals using these drugs need to be aware of the potential of fast rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment mass in about 18 months.
Weighing Treatments
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
Scientists note that individuals who shed pounds through lifestyle changes alone generally have a less rapid creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Experts suggest the mode of action of the injections explains the amplified rebound.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls hunger.
"Artificially providing the hormone levels far above than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating far more likely."
A Lifelong Disease?
Health authorities advise the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals argue that, due to the high risk of weight regain, the treatment might need to be life-long.
This opinion is echoed by pharmaceutical companies, who note that the results "highlight the persistent character of obesity," similar to managing conditions like high blood pressure.
User Accounts
People who have discontinued the medication explain a powerful resurgence of appetite.
"I experienced a trigger activating and you're instantly ravenous," recalled an individual.
This challenge is worsened if users have not developed sustainable lifestyle or habit modifications during therapy.
Growing Use
Survey data show that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is higher among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and long-term success relies on combined lifestyle support.
